TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03283072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: 15 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: 15 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: 15 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: 15 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: 15 bouts of 1mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: 15 bouts of 1mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: 15 bouts of 1mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: 15 bouts of 1mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: 8 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: 8 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: 8 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: 8 bouts of 2mins:1min hypoxia:hyperoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4 (sham)
Description: 15 bouts of 1min:1min normoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4 (sham)
Description: 15 bouts of 1min:1min normoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4 (sham)
Description: 15 bouts of 1min:1min normoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4 (sham)
Description: 15 bouts of 1min:1min normoxia
Study: NCT00743834

Intervention type: DRUG
Group type: OTHER
Intervention: Luvox CR
Description: In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Therapy
Description: The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
Study: NCT02252666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation Rehabilitation
Description: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Study: NCT03094416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine sodium capsule
Description: after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Description: for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium (LT4) Tablets
Description: during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
Study: NCT01664975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDPT regimen
Description: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Study: NCT02874521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-dialytic LF-EMS
Description: Electrical muscle stimulation during haemodialysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-dialytic cycle training
Description: Cycle training during haemodialysis
Study: NCT00926237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS - Sham repetitive transcranial magnetic stimulation
Description: Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS - Sham repetitive transcranial magnetic stimulation
Description: Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
Study: NCT04115306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMD-026
Description: Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: SERDs
Study: NCT01135173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waterpipe smoking cessation
Description: The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waterpipe smoking cessation
Description: The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
Study: NCT03558711

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: 18F-PET imaging
Study: NCT01736865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02279225

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group Phototherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phototherapy + Physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01957449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months.
Study: NCT02772406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light imaging
Study: NCT02318316

Intervention type: OTHER
Intervention: Exhaled breath condensate
Description: Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
Study: NCT05862220

Intervention type: DIAGNOSTIC_TEST
Intervention: D-Dimer vs CTPA
Description: CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.

Intervention type: DIAGNOSTIC_TEST
Intervention: D-Dimer vs CTPA
Description: CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
Study: NCT02761330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: Dose of the ECT charge will be determined during titration session prior to randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy
Description: Dose of the ECT charge will be determined during titration session prior to randomization.
Study: NCT00602602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02003924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth once daily

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sugar pill to mimic enzalutamide
Study: NCT01854411

Intervention type: OTHER
Intervention: analgesic measure
Description: ibuprofen and ketoprofen measured into breast milk
Study: NCT02574156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive insulin. However, the infusion flow will be different according to the group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will receive insulin. However, the infusion flow will be different according to the group.
Study: NCT00505284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, once daily, for 15 weeks (taken orally).
Study: NCT03317405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Apply to the skin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Apply to the skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05083234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing with SSO
Description: Vital signs of newborns in the sunflower seed oil group were measured. The skin of newborns in the sunflower seed oil group was wiped without rubbing. The skin of newborns in the sunflower seed oil group was evaluated with the NSCS scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing with LV
Description: Vital signs of newborns in the liquid vaseline group were measured. The skin of newborns in the liquid vaseline group was wiped without rubbing. The skin of newborns in the liquid vaseline group was evaluated with the NSCS scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The control group was not moisturized.
Description: Vital signs of newborns in the control group were measured. The skin of newborns in the control group was wiped without rubbing. The skin of newborns in the control group was evaluated with the NSCS scale.
Study: NCT03674411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU)
Description: 25 mg/m2 IV over 1 hour (\<10 kg: 0.83 mg/kg IV over 1 hour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: 60 mg/kg IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 165 cGy twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Description: Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5 ug/kg/d until the absolute neutrophil count (ANC) is \>2500/uL for 2 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m2/day (1.7 mg/kg/day if \< 10 kg) IV over 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGTA 456 Infusion
Description: The target cell dose is \>10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (\<18 years) and 8.1 × 108 cells/kg \[expanded product only\] for adults based on the highest cell dose windows evaluated in prior studies.
Study: NCT04036682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-081
Description: CLN-081 tablets
Study: NCT03911167

Intervention type: PROCEDURE
Intervention: open, laparoscopic, and robotic
Description: Radical resection of rectal cancer in robotic, laparoscopic, and open approach

Intervention type: PROCEDURE
Intervention: open, laparoscopic, and robotic
Description: Radical resection of rectal cancer in robotic, laparoscopic, and open approach

Intervention type: PROCEDURE
Intervention: open, laparoscopic, and robotic
Description: Radical resection of rectal cancer in robotic, laparoscopic, and open approach
Study: NCT02612272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: intra-articular ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: intra-articular betamethasone
Study: NCT01723982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban (FE 200440)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT04271852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bio-feedback treatment
Description: 50 patients will treated with phenix u2 and phenix u4 treating equipment。
Study: NCT02637245

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03783572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical evaluation
Description: For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation and Instrumental evaluation
Description: For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
Study: NCT02694185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caplan IVR
Description: This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.